Type 2 Diabetes Advanced Learning Center

Metformin May Reduce Delirium Risk in Older Adults with Type 2 Diabetes

Once-Weekly Insulin Efsitora Non-Inferior to Daily Degludec in HbA1c Reduction for T2D

Featured Content

Metformin May Reduce Delirium Risk in Older Adults with Type 2 Diabetes

Metformin May Reduce Delirium Risk in Older Adults with Type 2 Diabetes

November 22, 2024

Once-Weekly Insulin Efsitora Non-Inferior to Daily Degludec in HbA1c Reduction for T2D

Once-Weekly Insulin Efsitora Non-Inferior to Daily Degludec in HbA1c Reduction for T2D

October 14, 2024

Semaglutide Associated with Lower Risk for Certain Neurological/Psychiatric Disorders

Semaglutide Associated with Lower Risk for Certain Neurological/Psychiatric Disorders

August 22, 2024

FDA Approves Dapagliflozin as Glycemic Control Treatment for Type 2 Diabetes in Children

FDA Approves Dapagliflozin as Glycemic Control Treatment for Type 2 Diabetes in Children

July 09, 2024

Expanding Diabetes Care Through Pharmacy Partnerships in Public Health

Expanding Diabetes Care Through Pharmacy Partnerships in Public Health

May 22, 2024

Cardiovascular, Kidney Risks Among Individuals with Type 2 Diabetes Exacerbated by Excess Adiposity

Cardiovascular, Kidney Risks Among Individuals with Type 2 Diabetes Exacerbated by Excess Adiposity

April 10, 2024

Pharmacist-Led Intervention Reduces HbA1C Concentration in Hispanic Type 2 Diabetes Patients

Pharmacist-Led Intervention Reduces HbA1C Concentration in Hispanic Type 2 Diabetes Patients

January 01, 2024

GRADE: Trends, Challenges in Insulin Adoption Among Patients with Type 2 Diabetes

GRADE: Trends, Challenges in Insulin Adoption Among Patients with Type 2 Diabetes

January 01, 2024

Urgent Need for Early Treatment Intensification, Personalized Strategies in Diabetes Care

Urgent Need for Early Treatment Intensification, Personalized Strategies in Diabetes Care

January 01, 2024

Mobile Health Interventions Improve HbA1c Glucose Levels in African American, Latinx Patients with Diabetes

Mobile Health Interventions Improve HbA1c Glucose Levels in African American, Latinx Patients with Diabetes

January 01, 2024

Automated Insulin Delivery with Tubeless Patch-Pump and Remote CGM Feasible in Hospital Setting

Automated Insulin Delivery with Tubeless Patch-Pump and Remote CGM Feasible in Hospital Setting

January 01, 2024

Flash Monitoring Improves Glycemic Control Among Patients with Type 2 Diabetes

Flash Monitoring Improves Glycemic Control Among Patients with Type 2 Diabetes

January 01, 2024

SGLT2i Treatment Does Not Increase Fracture Risk in Postmenopausal Patients with Type 2 Diabetes

SGLT2i Treatment Does Not Increase Fracture Risk in Postmenopausal Patients with Type 2 Diabetes

October 25, 2023

Dorzagliatin Produces Type 2 Diabetes Remission in Certain Patients

Dorzagliatin Produces Type 2 Diabetes Remission in Certain Patients

August 29, 2023

SURMOUNT-2: Tirzepatide Significantly Reduces Weight in Patients with Type 2 Diabetes, Obesity

SURMOUNT-2: Tirzepatide Significantly Reduces Weight in Patients with Type 2 Diabetes, Obesity

July 17, 2023

MiniMed 78OG System with Guardian 4 Sensor Approved by FDA

MiniMed 78OG System with Guardian 4 Sensor Approved by FDA

June 07, 2023

FDA Clears IND Application for Covalent Menin Inhibitor Drug in Type 2 Diabetes

FDA Clears IND Application for Covalent Menin Inhibitor Drug in Type 2 Diabetes

January 24, 2023

ADA Updates Diabetes Standards of Care with New Recommendations, Inclusive Language for 2023

ADA Updates Diabetes Standards of Care with New Recommendations, Inclusive Language for 2023

January 24, 2023

Dorzagliatin Raises Insulin Secretion, Glucose Sensitivity

Dorzagliatin Raises Insulin Secretion, Glucose Sensitivity

January 23, 2023

FDA Issues Class I Recall for Omnipod DASH Insulin

FDA Issues Class I Recall for Omnipod DASH Insulin

December 15, 2022

FDA Greenlights New Diabetes Drug

FDA Greenlights New Diabetes Drug

December 07, 2022

Dapagliflozin Helps Preserve Kidney Function in Patients with Type 2 Diabetes

Dapagliflozin Helps Preserve Kidney Function in Patients with Type 2 Diabetes

October 06, 2022

Dapagliflozin Reduces CV Risk Regardless of CV Medication Use in Patients with T2D

Dapagliflozin Reduces CV Risk Regardless of CV Medication Use in Patients with T2D

September 07, 2022

Dulaglutide Alone Improves Glycemic Control in Young Patients with Type-2 Diabetes

Dulaglutide Alone Improves Glycemic Control in Young Patients with Type-2 Diabetes

August 04, 2022

First-Line SGLT-2 Inhibitor Therapy Has Benefits and Risks in Type 2 Diabetes

First-Line SGLT-2 Inhibitor Therapy Has Benefits and Risks in Type 2 Diabetes

July 07, 2022

COVID-19 Increases Risk of Diabetes

COVID-19 Increases Risk of Diabetes

May 06, 2022

When SGLT2i Therapy Fails, Adding Incretins May Be Better Than Switching Drug Class

When SGLT2i Therapy Fails, Adding Incretins May Be Better Than Switching Drug Class

April 06, 2022

Dapagliflozin Reduced New-Onset Type 2 Diabetes in Patients with Chronic Kidney Disease, Heart Failure

Dapagliflozin Reduced New-Onset Type 2 Diabetes in Patients with Chronic Kidney Disease, Heart Failure

March 02, 2022

Efpeglenatide Comparable to Liraglutide in Treatment Of Type 2 Diabetes

Efpeglenatide Comparable to Liraglutide in Treatment Of Type 2 Diabetes

January 20, 2022

CGM Bests Blood Glucose Monitoring Among Patients with Poorly Controlled Type 2 Diabetes

CGM Bests Blood Glucose Monitoring Among Patients with Poorly Controlled Type 2 Diabetes

December 22, 2021

Manufacturer Recalls Glucagon Emergency Kit Due to Potential Loss of Potency

Manufacturer Recalls Glucagon Emergency Kit Due to Potential Loss of Potency

December 22, 2021

New Type of Topical Cream Can Help Treat Diabetic Foot Ulcers

New Type of Topical Cream Can Help Treat Diabetic Foot Ulcers

December 22, 2021

Breaking News

Metformin May Reduce Delirium Risk in Older Adults with Type 2 Diabetes

Metformin May Reduce Delirium Risk in Older Adults with Type 2 Diabetes

November 22, 2024

Once-Weekly Insulin Efsitora Non-Inferior to Daily Degludec in HbA1c Reduction for T2D

Once-Weekly Insulin Efsitora Non-Inferior to Daily Degludec in HbA1c Reduction for T2D

October 14, 2024

Semaglutide Associated with Lower Risk for Certain Neurological/Psychiatric Disorders

Semaglutide Associated with Lower Risk for Certain Neurological/Psychiatric Disorders

August 22, 2024

FDA Approves Dapagliflozin as Glycemic Control Treatment for Type 2 Diabetes in Children

FDA Approves Dapagliflozin as Glycemic Control Treatment for Type 2 Diabetes in Children

July 09, 2024

Type 2 Diabetes Videos

FDA Adds Intestinal Blockage, Hypoglycemia Warning in Semaglutide Label Update

FDA Adds Intestinal Blockage, Hypoglycemia Warning in Semaglutide Label Update

January 01, 2024

Vitamin D Deficiency Linked to Increased Heart Failure Risk in Patients with Diabetes

Vitamin D Deficiency Linked to Increased Heart Failure Risk in Patients with Diabetes

January 01, 2024

GRADE: Glargine, Liraglutide Significantly Decrease Glycated Hemoglobin When Combined with Metformin

GRADE: Glargine, Liraglutide Significantly Decrease Glycated Hemoglobin When Combined with Metformin

January 24, 2023

Pemafibrate Significantly Reduces Triglyceride Levels in Adults with Type 2 Diabetes with No Positive Impact on CVD

Pemafibrate Significantly Reduces Triglyceride Levels in Adults with Type 2 Diabetes with No Positive Impact on CVD

January 24, 2023

Test Your Knowledge

More Content

Metformin May Reduce Delirium Risk in Older Adults with Type 2 Diabetes

Metformin May Reduce Delirium Risk in Older Adults with Type 2 Diabetes

November 22, 2024

Once-Weekly Insulin Efsitora Non-Inferior to Daily Degludec in HbA1c Reduction for T2D

Once-Weekly Insulin Efsitora Non-Inferior to Daily Degludec in HbA1c Reduction for T2D

October 14, 2024

Semaglutide Associated with Lower Risk for Certain Neurological/Psychiatric Disorders

Semaglutide Associated with Lower Risk for Certain Neurological/Psychiatric Disorders

August 22, 2024

FDA Approves Dapagliflozin as Glycemic Control Treatment for Type 2 Diabetes in Children

FDA Approves Dapagliflozin as Glycemic Control Treatment for Type 2 Diabetes in Children

July 09, 2024

Expanding Diabetes Care Through Pharmacy Partnerships in Public Health

Expanding Diabetes Care Through Pharmacy Partnerships in Public Health

May 22, 2024

Cardiovascular, Kidney Risks Among Individuals with Type 2 Diabetes Exacerbated by Excess Adiposity

Cardiovascular, Kidney Risks Among Individuals with Type 2 Diabetes Exacerbated by Excess Adiposity

April 10, 2024

Pharmacist-Led Intervention Reduces HbA1C Concentration in Hispanic Type 2 Diabetes Patients

Pharmacist-Led Intervention Reduces HbA1C Concentration in Hispanic Type 2 Diabetes Patients

January 01, 2024

GRADE: Trends, Challenges in Insulin Adoption Among Patients with Type 2 Diabetes

GRADE: Trends, Challenges in Insulin Adoption Among Patients with Type 2 Diabetes

January 01, 2024

Urgent Need for Early Treatment Intensification, Personalized Strategies in Diabetes Care

Urgent Need for Early Treatment Intensification, Personalized Strategies in Diabetes Care

January 01, 2024

Mobile Health Interventions Improve HbA1c Glucose Levels in African American, Latinx Patients with Diabetes

Mobile Health Interventions Improve HbA1c Glucose Levels in African American, Latinx Patients with Diabetes

January 01, 2024

Automated Insulin Delivery with Tubeless Patch-Pump and Remote CGM Feasible in Hospital Setting

Automated Insulin Delivery with Tubeless Patch-Pump and Remote CGM Feasible in Hospital Setting

January 01, 2024

FDA Adds Intestinal Blockage, Hypoglycemia Warning in Semaglutide Label Update

FDA Adds Intestinal Blockage, Hypoglycemia Warning in Semaglutide Label Update

January 01, 2024

Vitamin D Deficiency Linked to Increased Heart Failure Risk in Patients with Diabetes

Vitamin D Deficiency Linked to Increased Heart Failure Risk in Patients with Diabetes

January 01, 2024

Flash Monitoring Improves Glycemic Control Among Patients with Type 2 Diabetes

Flash Monitoring Improves Glycemic Control Among Patients with Type 2 Diabetes

January 01, 2024

SGLT2i Treatment Does Not Increase Fracture Risk in Postmenopausal Patients with Type 2 Diabetes

SGLT2i Treatment Does Not Increase Fracture Risk in Postmenopausal Patients with Type 2 Diabetes

October 25, 2023

Dorzagliatin Produces Type 2 Diabetes Remission in Certain Patients

Dorzagliatin Produces Type 2 Diabetes Remission in Certain Patients

August 29, 2023

SURMOUNT-2: Tirzepatide Significantly Reduces Weight in Patients with Type 2 Diabetes, Obesity

SURMOUNT-2: Tirzepatide Significantly Reduces Weight in Patients with Type 2 Diabetes, Obesity

July 17, 2023

MiniMed 78OG System with Guardian 4 Sensor Approved by FDA

MiniMed 78OG System with Guardian 4 Sensor Approved by FDA

June 07, 2023

GRADE: Glargine, Liraglutide Significantly Decrease Glycated Hemoglobin When Combined with Metformin

GRADE: Glargine, Liraglutide Significantly Decrease Glycated Hemoglobin When Combined with Metformin

January 24, 2023

Pemafibrate Significantly Reduces Triglyceride Levels in Adults with Type 2 Diabetes with No Positive Impact on CVD

Pemafibrate Significantly Reduces Triglyceride Levels in Adults with Type 2 Diabetes with No Positive Impact on CVD

January 24, 2023

FDA Clears IND Application for Covalent Menin Inhibitor Drug in Type 2 Diabetes

FDA Clears IND Application for Covalent Menin Inhibitor Drug in Type 2 Diabetes

January 24, 2023

ADA Updates Diabetes Standards of Care with New Recommendations, Inclusive Language for 2023

ADA Updates Diabetes Standards of Care with New Recommendations, Inclusive Language for 2023

January 24, 2023

Dorzagliatin Raises Insulin Secretion, Glucose Sensitivity

Dorzagliatin Raises Insulin Secretion, Glucose Sensitivity

January 23, 2023

FDA Issues Class I Recall for Omnipod DASH Insulin

FDA Issues Class I Recall for Omnipod DASH Insulin

December 15, 2022

FDA Greenlights New Diabetes Drug

FDA Greenlights New Diabetes Drug

December 07, 2022

Dapagliflozin Helps Preserve Kidney Function in Patients with Type 2 Diabetes

Dapagliflozin Helps Preserve Kidney Function in Patients with Type 2 Diabetes

October 06, 2022

Dapagliflozin Reduces CV Risk Regardless of CV Medication Use in Patients with T2D

Dapagliflozin Reduces CV Risk Regardless of CV Medication Use in Patients with T2D

September 07, 2022

Dulaglutide Alone Improves Glycemic Control in Young Patients with Type-2 Diabetes

Dulaglutide Alone Improves Glycemic Control in Young Patients with Type-2 Diabetes

August 04, 2022

First-Line SGLT-2 Inhibitor Therapy Has Benefits and Risks in Type 2 Diabetes

First-Line SGLT-2 Inhibitor Therapy Has Benefits and Risks in Type 2 Diabetes

July 07, 2022

COVID-19 Increases Risk of Diabetes

COVID-19 Increases Risk of Diabetes

May 06, 2022

When SGLT2i Therapy Fails, Adding Incretins May Be Better Than Switching Drug Class

When SGLT2i Therapy Fails, Adding Incretins May Be Better Than Switching Drug Class

April 06, 2022

Dapagliflozin Reduced New-Onset Type 2 Diabetes in Patients with Chronic Kidney Disease, Heart Failure

Dapagliflozin Reduced New-Onset Type 2 Diabetes in Patients with Chronic Kidney Disease, Heart Failure

March 02, 2022

Efpeglenatide Comparable to Liraglutide in Treatment Of Type 2 Diabetes

Efpeglenatide Comparable to Liraglutide in Treatment Of Type 2 Diabetes

January 20, 2022

ADA: Collaborative Care Key to Diabetes, Comorbidities Management

ADA: Collaborative Care Key to Diabetes, Comorbidities Management

January 12, 2022

CGM Bests Blood Glucose Monitoring Among Patients with Poorly Controlled Type 2 Diabetes

CGM Bests Blood Glucose Monitoring Among Patients with Poorly Controlled Type 2 Diabetes

December 22, 2021

Manufacturer Recalls Glucagon Emergency Kit Due to Potential Loss of Potency

Manufacturer Recalls Glucagon Emergency Kit Due to Potential Loss of Potency

December 22, 2021

New Type of Topical Cream Can Help Treat Diabetic Foot Ulcers

New Type of Topical Cream Can Help Treat Diabetic Foot Ulcers

December 22, 2021